Skip to end of metadata
Go to start of metadata


The objective of the study is to determine if men with evidence of progressive prostate cancer while on chronic androgen ablation of = 1 year duration will exhibit a clinical response following administration of parenteral testosterone and oral etoposide.  Eligible patients will have castrate resistant prostate cancer with minimal disease (rising PSA and = 5 total sites of metastases in bone, lymph node and soft tissue) on continuous castrating androgen ablative therapy for = 1 yr; allowed = 2 prior chemo; allowed = 2 prior second line HT; off antiandrogens for = 6weeks



Johns Hopkins Hospital

Principal Investigator:

Samuel Denmeade, M.D.

  • None